Time will tell if the once-daily, 14-day oral treatment could be a breakthrough for patients with depression.
Zuranolone, a recently FDA-approved medication for postpartum depression, is showing promise in the treatment of major depressive disorder (MDD). The drug’s impact extends beyond symptom reduction, enhancing the daily lives of patients and hinting at broader implications for mental health treatment.
- Zuranolone is a once-daily, 14-day oral treatment currently in clinical development for adults with MDD.
- The study involved 32 adults with MDD who showed a clinical response to 50-mg once-daily zuranolone.
- All patients reported improvement in one or more MDD symptoms with zuranolone.
- 87.5% of patients noticed improvements within the first week of treatment.
- Prior to receiving zuranolone, 27 patients experienced adverse MDD-related symptoms affecting their social lives, activities, or relationships. Following treatment, they all reported improvement in those areas.
All participants agreed seeing improvements within a short time period was meaningful to them. Of the 29 patients who described what they most liked about zuranolone, many liked that it helped manage their depression or another specific MDD-related symptom and the 14-day treatment course.
— First author Amanda McDaniel, PMHNP-BC, of the Caprock Alliance for Mental Wellness, and coauthors
More on Depression